Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The event will be held both in-person and virtually. Steven Quay, M.D., Ph.D., President and CEO of Atossa, will take part in a virtual fireside chat and meet with investors.

A recording of the fireside chat will be available at 7:00 a.m. EDT on Monday, September 9, 2024, on the conference website and in the Investors section of Atossa's website under Events & Presentations. Investors interested in one-on-one meetings with Atossa management should contact their H.C. Wainwright representative to arrange appointments.

SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event, scheduled for September 9-11, 2024, will be held both in-person and virtually.

Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat and meet with investors. A recording of the fireside chat will be available here at 7:00 a.m. EDT on Monday, September 9, 2024 or in the Investors section of the Company’s website under Events & Presentations. Investors wishing to arrange one-on-one meetings with Atossa management should contact their H.C. Wainwright representative.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “future,” or other comparable words. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, such as data related to the (Z)-endoxifen program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, and potential milestones and growth opportunities for the Company, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim and final clinical results; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Contact:

Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com

FAQ

When is Atossa Therapeutics (ATOS) presenting at the H.C. Wainwright Global Investment Conference?

Atossa Therapeutics (ATOS) is participating in the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9-11, 2024.

Who will represent Atossa Therapeutics (ATOS) at the H.C. Wainwright conference?

Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa Therapeutics, will represent the company at the conference.

How can investors access Atossa Therapeutics' (ATOS) fireside chat from the H.C. Wainwright conference?

A recording of the fireside chat will be available at 7:00 a.m. EDT on Monday, September 9, 2024, on the conference website and in the Investors section of Atossa's website under Events & Presentations.

Can investors arrange one-on-one meetings with Atossa Therapeutics (ATOS) management at the H.C. Wainwright conference?

Yes, investors wishing to arrange one-on-one meetings with Atossa management should contact their H.C. Wainwright representative.